DAB2IP and hepatocellular carcinoma: Notably, our group’s previous work demonstrated that EZH2, an upstream inhibitory regulatory protein of DAB2IP, serves as a promising diagnostic biomarker for hepatocellular carcinoma [18] and supports nasopharyngeal carcinoma cell aggressiveness [19].